Active Biotech's election committee appointedNovember 3, 2010 14:00 (CET)
In accordance with a decision made by the Annual General Meeting held on May 6, 2010, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September, and the Chairman of the Board.
For the 2011 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:
Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Peter Thelin, Brummer & Partners
Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals for the Board of Directors that are to be presented to and decided upon at the Annual General Meeting on May 5, 2011.
Lund, November 3, 2010
Active Biotech AB (publ)
President and CEO
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on November 3, 2010 at 2:00 p.m.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00